KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Change in Intangibles (2016 - 2020)

Pfizer (PFE) has disclosed Change in Intangibles for 8 consecutive years, with $38.0 million as the latest value for Q3 2020.

  • Quarterly Change in Intangibles fell 60.82% to $38.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $125.0 million through Sep 2020, down 73.35% year-over-year, with the annual reading at $539.0 million for FY2020, 28.95% up from the prior year.
  • Change in Intangibles for Q3 2020 was $38.0 million at Pfizer, up from $1.0 million in the prior quarter.
  • The five-year high for Change in Intangibles was $158.0 million in Q1 2019, with the low at $1.0 million in Q2 2020.
  • Average Change in Intangibles over 5 years is $74.1 million, with a median of $76.5 million recorded in 2016.
  • The sharpest move saw Change in Intangibles soared 1820.0% in 2016, then plummeted 99.08% in 2020.
  • Over 5 years, Change in Intangibles stood at $80.0 million in 2016, then fell by 8.75% to $73.0 million in 2017, then surged by 43.84% to $105.0 million in 2018, then plummeted by 48.57% to $54.0 million in 2019, then decreased by 29.63% to $38.0 million in 2020.
  • According to Business Quant data, Change in Intangibles over the past three periods came in at $38.0 million, $1.0 million, and $32.0 million for Q3 2020, Q2 2020, and Q1 2020 respectively.